PCRX logo

Pacira BioSciences Inc. (PCRX)

$36.48

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on PCRX

Market cap

$1.46B

EPS

0.94

P/E ratio

100.8

Price to sales

1.94

Dividend yield

--

Beta

0.216721

Price on PCRX

Previous close

$36.48

Today's open

--

Day's range

--

52 week range

$18.80 - $36.67

Profile about PCRX

CEO

Frank D. Lee

Employees

829

Headquarters

Brisbane, CA

Exchange

Nasdaq Global Select

Shares outstanding

40094660

Issue type

Common Stock

PCRX industries and sectors

Healthcare

Pharmaceuticals

News on PCRX

Viatris Completes Acquisition of Pacira BioSciences

PITTSBURGH, Nov. 17, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that it has completed its acquisition of Pacira BioSciences, Inc. ("Pacira") (Nasdaq: PCRX), a leader in non-opioid pain management. The transaction was first announced on Oct. 8, 2026.

news source

PRNewsWire • Nov 17, 2026

news preview

Viatris Reports Third-Quarter 2026 Financial Results

Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Japan Returns Approximately $717 Million of Capital to Shareholders Year to Date, Including Through Share Repurchases Advances Innovative Medicines Strategy with Planned Acquisition of Pacira BioSciences, Expected to Close by the End of November Raises 2026 Financial Guidance Midpoints for All Metrics [1] PITTSBURGH, Nov. 5, 2026 /PRNewswire/ -- Viatris Inc.  (Nasdaq: VTRS), a global healthcare company, today announced its third-quarter 2026 financial results. Executive Commentary "Our third-quarter results reflect strong execution and reinforce our confidence in the growth trajectory of our business," said Scott A.

news source

PRNewsWire • Nov 5, 2026

news preview

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it are.

news source

Business Wire • Nov 5, 2026

news preview

INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered on the 47th floor in the Empire State Building in New York City and are investigating if below deal is fair:

news source

GlobeNewsWire • Nov 4, 2026

news preview

PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash. Halper Sadeh encourages Pacira shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Pacira and its board of directors violated t.

news source

Business Wire • Oct 31, 2026

news preview

Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.

PITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of Pacira BioSciences, Inc. ("Pacira") (Nasdaq: PCRX), for $36.50 per Share, in cash, net of applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated Oct. 30, 2026 (as it may be amended or supplemented from time to time, the "Offer to Purchase"), and the accompanying Letter of Transmittal (the "Letter of Transmittal" and, together with the Offer to Purchase and other related materials, as they may be amended or supplemented from time to time, the "Offer"). The Offer is being made pursuant to the Agreement and Plan of Merger, dated Oct. 8, 2026, by and among Viatris, Purchaser and Pacira (as it may be amended or supplemented from time to time, the "Merger Agreement").

news source

PRNewsWire • Oct 30, 2026

news preview

Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth

Pacira BioSciences (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 29, 2026

news preview

Top 3 Health Care Stocks That May Fall Off A Cliff In October

As of Oct. 16, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

news source

Benzinga • Oct 16, 2026

news preview

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)

NEW YORK, Oct. 11, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Pacira BioSciences, Inc. (NASDAQ: PCRX ) related to its sale to Viatris Inc. Under the terms of the proposed transaction, Pacira shareholders are expected to receive $36.50 in cash per share.

news source

PRNewsWire • Oct 11, 2026

news preview

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.

news source

Zacks Investment Research • Oct 9, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Pacira BioSciences Inc.

Open an M1 investment account to buy and sell Pacira BioSciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in PCRX on M1